Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

An innovative, minimally invasive medical device used for treatment of Benign Prostatic Hyperplasia symptoms.

Project description

A minimally invasive approach for treating enlarged prostate

The prostate is a gland that is located between the bladder and the penis. Sometimes this gland becomes enlarged, which may cause bladder irritability, erectile dysfunction or even infertility. Current surgical procedures are invasive and costly. The EU-funded ClearRing project has developed a novel ring-based solution that can be embedded within the prostate tissue from the urethra through a minimally invasive approach. The ClearRing solution expands the constricted prostate region and relieves symptoms. Importantly, the procedure is fast and does not require hospitalisation, with obvious benefits for both patients and healthcare systems.

Objective

There are approximately 30 million men worldwide who experience moderate to severe Benign Prostatic Hyperplasia (BPH) symptoms. These symptoms, such as urgent need to urinate, difficulty starting urination, weak stream, or increased frequency of urination, are severe enough to disrupt a patient’s daily lifestyle. Of the 30 million sufferers, an estimated 25% require immediate active treatment. Transurethral Resection of the Prostate (TURP), the current gold standard procedure, is costly, ineffective, and can lead to harsh side effects such as infertility, erectile dysfunction, and bladder irritability, while alpha blockers can lead to weakness, dizziness, and headaches. Therefore, there is a significant unmet need for minimally invasive BPH therapy as a less costly, tolerable, and safe alternative to drugs and surgery. Pro Arc Medical is introducing the ClearRing system, designed to expand the prostate and provide immediate relief of BPH symptoms. Because all of the tools necessary are located within the housing of the elongated shaft, the device can easily be inserted and removed without the need for extraneous procedures. The ClearRing system will bring an immediate cost reduction and time advantage to surgeons and hospitals. The minimally invasive procedure will reduce the range and severity of side effects allowing patients to resume their normal lifestyles potentially twice as fast as the current standard operation procedure. During the feasibility assessment, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. Pro Arc will upgrade the ClearRing system, as well as optimize the system in order to allow for two implants to be inserted at the same time during the second phase of innovation project. A clinical trial will then be initiated to obtain ISO 13845 and CE mark.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

SME-1 - SME instrument phase 1

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-SMEInst-2016-2017

See all projects funded under this call

Coordinator

PROARC MEDICAL LTD
Net EU contribution
€ 50 000,00
Address
KIDMA 23
3707923 PARDES HANA
Israel
SME
Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 71 429,00